Clinical Trial Update: Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study of REGN2810 in patients with advanced cutaneous squamous cell carcinoma has completed, with results posted in December 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma

Drugs mentioned

• Libtayo (cemiplimab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Advanced Cutaneous Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2024-12-11